Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
Clinical trial NCT01808950 · TERMINATED
Trial details
- NCT number
- NCT01808950
- Sponsor
- Spirig Pharma Ltd.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-02-01
- Primary completion
- 2013-08-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.